Trial reportJournal of neuro-oncology2011
High dose methotrexate for pediatric high grade glioma: results of the HIT-GBM-D pilot study.
Trial report in Journal of neuro-oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Treatment of Children and Adolescents With Diffuse Intrinsic Pontine Glioma and High Grade Glioma
Phase 2 Randomized Study of RT and Reirradiation at Relapse vs Multiple Elective RT Courses With Same Concomitant CT for Newly Diagnosed
Who cites it
25 citing papers in PubMed, 54 citations in OpenAlex.
- Understanding DMG: current treatment options and prospective solutions using nanoparticles.Drug delivery and translational research · 2026Review
- High expression of LncRNA HOTAIR is a risk factor for temozolomide resistance in glioblastoma via activation of the miR-214/β-catenin/MGMT pathway.Scientific reports · 2024Article
- Intraventricular dimethyl sulfoxide (DMSO) induces hydrocephalus in a dose-dependent pattern.Heliyon · 2024Article
- How I treat recurrent pediatric high-grade glioma (pHGG): a Europe-wide survey study.Journal of neuro-oncology · 2023Article
- The tumor micro-environment in pediatric glioma: friend or foe?Frontiers in immunology · 2023Review
- Infiltrative gliomas of the thalamus in children: the role of surgery in the era of H3 K27M mutant midline gliomas.Acta neurochirurgica · 2021Article
- Article
- Integrated systems-genetic analyses reveal a network target for delaying glioma progression.Annals of clinical and translational neurology · 2019Article
- Does the interval from tumour surgery to radiotherapy influence survival in paediatric high grade glioma?Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2018Article
- Concurrent radiotherapy with temozolomide vs. concurrent radiotherapy with a cisplatinum-based polychemotherapy regimen : Acute toxicity in pediatric high-grade glioma patients.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2018Article
- Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.Neuro-oncology · 2018Article
- High-grade glioma in very young children: a rare and particular patient population.Oncotarget · 2017Review
- Methotrexate up-regulates ecto-5'-nucleotidase/CD73 and reduces the frequency of T lymphocytes in the glioblastoma microenvironment.Purinergic signalling · 2016Article
- DIPG in Children - What Can We Learn from the Past?Frontiers in oncology · 2015Review
- Managing teenage/young adult (TYA) brain tumors: a UK perspective.CNS oncology · 2015Review
- Management of high-grade gliomas in the pediatric patient: Past, present, and future.Neuro-oncology practice · 2014Article
- Role of methamphetamine on glioblastoma cytotoxicity induced by doxorubicin and methotrexate.Neurotoxicity research · 2014Article
- The effect of ABCG2 and ABCC4 on the pharmacokinetics of methotrexate in the brain.Drug metabolism and disposition: the biological fate of chemicals · 2014Article
- Management of diffuse pontine gliomas in children: recent developments.Paediatric drugs · 2013Review
- Cerebellar location may predict an unfavourable prognosis in paediatric high-grade glioma.British journal of cancer · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 8 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We conducted a phase II study to test methotrexate (5 g/m(2)), as a single agent prior to radiochemotherapy for pediatric high-grade glioma and diffuse intrinsic pontine glioma. Thirty patients (19 male, median age 10.8) were enrolled. Tumors were located as follows: cortex 10, pons 7, other 13. Tumor resection was classified as gross total in 6, subtotal in 6, partial in 4, biopsy in 11 and not performed in 3. WHO grading of the histology was: IV: 11, III: 12 and II: 3. Patients received methotrexate 5 g/m(2) in 24-hour infusions on days 1 and 15. Subsequently 54 Gy radiation was administered with simultaneous chemotherapy including cisplatin, etoposide, vincristine and ifosfamide as previously described. Eight 6-weeks cycles of maintenance chemotherapy consisted of vincristine 1.5 mg/m(2) on days 1, 8 and 15; lomustine 100 mg/m(2) on day 2 and prednisone 40 mg/kg on days 1-17. Event-free survival rates in the whole group of 30 patients were: 43, 20, and 13% after 1, 2 and 5 years, respectively. The response evaluation after methotrexate was available in 19 of the 24 patients who started treatment with measurable disease: CR: 0, PR: 1, SD 18, PD: 0. After radiochemotherapy the response of 24 patients with measurable disease was CR: 1, PR 10, SD 12, PD 1. Both response and event-free survival were superior to the control group of 330 patients treated in various protocols of the same cooperative group. In subgroup analyses the use of dexamethasone during early treatment was linked to poor event free survival. Giving two cycles of high-dose methotrexate prior to radiochemotherapy was feasible, and the approach was taken forward to a randomized phase III trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.